Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2016 08:00 ET | Source: Advaxis

Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations

PRINCETON, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that preclinical data on the...
November 15, 2016 08:00 ET | Source: Advaxis

Advaxis to Present at the Jefferies 2016 London Healthcare Conference

PRINCETON, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel O’Connor,...
November 11, 2016 07:30 ET | Source: Advaxis

Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Phase 1 AXAL and durvalumab combination trial shows safety and tolerability in cervical and HPV+ head and neck cancerPreclinical data demonstrate synergistic antitumor effects of AXAL combined with a...
October 24, 2016 08:00 ET | Source: Advaxis

Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

Data in 50 patients with recurrent metastatic carcinoma of the cervix demonstrates a 52% increase in 12-month overall survival rate PRINCETON, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc....
October 20, 2016 07:30 ET | Source: Advaxis

Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck

KEYNOTE-046 study to evaluate KEYTRUDA® in combination with ADXS-PSA Advaxis begins screening patients for Phase 3 AIM2CERV study in cervical cancer PRINCETON, N.J., Oct. 20, 2016 (GLOBE...
October 13, 2016 08:00 ET | Source: Advaxis

Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program

PRINCETON, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $2.7...
October 11, 2016 08:00 ET | Source: Advaxis

Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster

Reception to also feature update on ADXS-NEO: Personalizing Immunotherapy PRINCETON, N.J., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company...
October 06, 2016 08:00 ET | Source: Advaxis

Advaxis CSO Invited to Speak at Immune Profiling World Congress

PRINCETON, N.J., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Robert Petit, Ph.D.,...
October 03, 2016 08:00 ET | Source: Advaxis

Advaxis Appoints Christopher Duke as Chief Operating Officer

Greg Mayes Becomes Company’s First Chief Business Officer PRINCETON, N.J., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer...
September 26, 2016 15:45 ET | Source: Advaxis

Advaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting

PRINCETON, N.J., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced three poster...